Patients with tumors in the trigone and urethra were more likely to experience recurrence and cancer-specific death after radical cystectomy than patients with tumor only in the bladder walls.

Trigone Pharma, a pharmaceutical company dedicated to developing novel solutions that treat bladder cancers and urologic diseases, and 4C Biomed, an early-stage biomed R&D group specializing in ...

TRG-100 is now being evaluated in broad range of bladder disordersRAANANA, Israel, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma Ltd. a leader in the field of urological diseases, today ...

Trigonitis occurs when tissue in the lower part of your bladder near the opening of the urethra becomes inflamed. Symptoms are similar to those of other conditions, such as urinary tract ...

Background A 32-year-old healthy woman from China was diagnosed with a bladder mass during pelvic ultrasonography, carried out during the work-up of a miscarriage. Cystoscopy by the Department of ...

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

All other parts of the bladder mucosa showed no abnormalities or signs of exophytic tumor growth. Bimanual palpation revealed a manipulatable mass between the uterus and the bladder.

Relmada Therapeutics announced a licensing agreement for NDV-01, a new treatment for non-muscle invasive bladder cancer. Phase 2 data expected in April 2025. Quiver AI Summary Relmada Therapeutics ...

TRG-100 is a proprietary combination drug administered directly into the bladder, designed to locally treat the chronic pain and the complexity of IC/BPS rapidly, to improve patients' quality of life.

“We believe Trigone’s novel intravesicular sustained-release formulation could enable NDV-01 to be a first-line therapy for non-muscle invasive bladder cancer, supported by several ...